November 3, 2020 07:15 AM ESTUpdated November 4, 04:02 AM
Coronavirus

Covid-19 roundup: CEPI pours $328M in­to Clover's vac­cine; For­mer Shkre­li com­pa­ny li­cens­es po­ten­tial treat­ment for $20M

Nicole DeFeudis

Editor

Af­ter pour­ing $69.5 mil­lion in­to the de­vel­op­ment Clover Bio­phar­ma­ceu­ti­cals’ Covid-19 vac­cine, CEPI is back with an­oth­er $250 mil­lion-plus to fin­ish what it start­ed.

The lat­est …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Post-Hoc: Big Phar­ma is los­ing the AI tal­ent war

Four biotechs emerge with $800M and in-li­censed as­sets on Fri­day

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

A service from the Financial Times